Skip to content

Effect of perioperative esketamine on postoperative cognitive function in elderly patients undergoing gastrointestinal cancer surgeryanism Study Based on Intestinal Flora and Bile Acid Metabolism

Effect of perioperative esketamine on postoperative cognitive function in elderly patients undergoing gastrointestinal cancer surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097651
Enrollment
Unknown
Registered
2025-02-24
Start date
2025-02-27
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction

Interventions

Test group:Anesthesia maintenance: During the operation, sevoflurane was inhaled at a concentration of 1.5%-3% and remifentanil was continuously pumped with 0.01-0.02µg/(kg·min) to maintain anesthesia
Control group:Anesthesia maintenance: During the operation, sevoflurane was inhaled at a concentration of 1.5%-3% and remifentanil was continuously pumped with 0.01-0.02µg/(kg·min) to maintain anesthe
Analgesic pump parameter settings: first dose 2ml, background dose 2.5ml/h, patient-controlled analgesia (PCA) dose 2ml, lock-in time 30min.

Sponsors

General Hospital of Western Theater Command of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=65 years old; 2. American Society of Anesthesiologists (ASA) grade I-III; 3. Patients with indications for gastrointestinal tumor resection; 4. All patients received postoperative analgesia; 5. All patients or their family members voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1.ASA grade > III; 2. Previous history of stroke, cerebral infarction or TIA; Obstructive sleep apnea syndrome; 3. Patients with infectious diseases or hematological diseases; 4. Patients with end-stage chronic disease, severe pulmonary hypertension, acute myocardial infarction; 5. Patients with contraindications to surgery and anesthesia; 6. Patients with senile dementia, Alzheimer's disease and other brain degenerative diseases; 7. Those with mental disorder or mental illness who are unable to cooperate.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment Score;Mini-mental State Examination Score;Interleukin-6 expression levels in serology;S100ß protein content in serology;

Secondary

MeasureTime frame
Gut microbiota;Quantitative of serum bile acids;

Countries

China

Contacts

Public ContactLibang Yuan

General Hospital of Western Theater Command of PLA

lemonbang@126.com+86 134 5866 5896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026